ProMIS Neurosciences Targets Misfolded Protein in ALS Research Effort
ProMIS Neurosciences announced the start of a research program to identify new therapeutic targets on neurotoxic strains of a protein, TDP43, implicated in the development…
Articles by Margarida Azevedo, MSc
ALS Scientists Say Older Stem Cells Will Offer More Accurate Results as They Seek Treatments
Scientists at Cedars-Sinai Board of Governors Regenerative Medicine Institute who are researching methods for enhancing stem cell models for amyotrophic lateral…
Animal Model ALS Genetics Leading to Personalized Medicine for Humans
Researchers reviewed the strengths and weaknesses of animal models currently used for ALS research, in the study “From animal…
Brainstorm’s NurOwn for ALS Gets High Marks in Phase 2 Trial
BrainStorm Cell Therapeutics reported data from its recently completed Phase 2 clinical trial of NurOwn in 48 patients with amyotrophic…
Researchers Find Autoimmune Role of Gene Central to ALS, Emphasize Need for Clinical Trials
Researchers at the Harvard Stem Cell Institute (HSCI), along with colleagues at the Broad Institute of MIT and Harvard, conducted…
Gut Microbiome May Be Key for Neurological Health, Therapy: An Interview
In a recent interview, Dr. David Perlmutter discussed new and exciting gut microbiome theories that could change the way the medical…
ALS Affects Visual Pathways and by Degree That May Serve as Disease Biomarker, Study Finds
Whether the damage done by amyotrophic lateral sclerosis (ALS) also affects visual pathways, namely the macula, is a matter of debate…
Noninvasive Ventilation and Posture Influence Respiratory Ability in ALS Patients
Researchers who studied noninvasive ventilation (NIV) in patients with amyotrophic lateral sclerosis (ALS) found that respiratory muscles may work more efficiently during…
Science on a Chip: Lab Platform for ALS Study Lets Researchers Make Muscle Fibers in Gelatin
Scientists at the University of Southern California have developed a laboratory model of skeletal muscle, fabricated on a tiny chip molded in…
FDA Acts to Speed Development of Herantis Pharma’s Potential Treatment for ALS
Herantis Pharma announced that a pipeline therapy known as cerebral dopamine neurotrophic factor (CDNF) has been granted Orphan Drug Status by the…